Close button
Logo
Discount sale Liver Diseases Therapeutics Market Size And Forecast To 2027

Liver represents the largest organ of the body performing a wide variety of roles that include converting food into energy, creating bile for proper digestion of food, and detoxifying alcohol and poisons from the blood. There are several kinds of liver diseases such as hepatitis A, hepatitis B, and hepatitis C; liver fibrosis, liver cancer; fatty liver disease and cirrhosis; hemochromatosis and Wilson disease.

The global liver diseases therapeutics market is estimated to account for US$ 12,851.3 Mn in terms of value in 2020 and is expected to reach US$ 24,921.3 Mn by the end of 2027.

Global Liver Diseases Therapeutics Market: Drivers

Increasing prevalence of liver cancer is expected to propel growth of the global liver diseases therapeutics market over the forecast period. For instance, according to The American Cancer Society, in 2020, the U.S. is expected to record around 42,810 new cases and around 30,160 deaths due to primary liver cancer and intrahepatic bile duct cancer.

Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034.        

North America held dominant position in the global liver diseases therapeutics market in 2019, accounting for 38.6% share in terms of value, followed by Europe and Asia Pacific, respectively

Figure 1. Global Liver Disease Therapeutics Market Share (%), by Region, 2019

Liver Diseases Therapeutics  | Coherent Market Insights

Global Liver Diseases Therapeutics Market: Restraints

Side effects and risks associated with liver diseases therapeutics is expected to hinder growth of the global liver diseases therapeutics market. The side effects associated with the use of liver therapeutics include, nausea, headache, fever loss of appetite, and drug-induced liver disease.

Moreover, availability of alternate treatment procedures such as organ transplantation and liver resection is also expected to limit growth of the market.

Global Liver Diseases Therapeutics Market: Opportunities 

R&D in immunotoxins is expected to offer lucrative growth opportunities for players in the global liver diseases therapeutics market. For instance, GPC3 is a cell surface heparan sulfate proteoglycan that is overexpressed in hepatocellular carcinoma. Anti-GPC3 immunotoxins can be effective in the treatment of human hepatocellular carcinoma.

Moreover, clinical trials for development of new therapies is also expected to aid in growth of the market. For instance, in March 2018, the U.S. FDA granted Orphan Drug Designation for Protagonist Therapeutics, Inc.’s PTG-300: a subcutaneous injectable in clinical development stage for the potential treatment of beta-thalassemia and liver fibrosis.

The global liver diseases therapeutics market was valued at US$ 11,854.7 Mn in 2019 and is forecast to reach a value of US$ 24,921.3 Mn by 2027 at a CAGR of 9.7% between 2020 and 2027.

Figure 2. Global Liver Disease Therapeutics Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

Liver Diseases Therapeutics  | Coherent Market Insights

Market Trends/Key Takeaways

Major organizations are focused on providing treatment guidelines for liver diseases during the COVID-19 pandemic. For instance, in March 2020, The American Association for the Study of Liver Disease released a clinical insight document for clinicians and frontline healthcare providers engaged in the treatment of patients with liver disease during the COVID-19 pandemic.

Increasing consumption of alcohol is expected to aid in growth of the market. For instance, according to the 2018 National Survey on Drug Use and Health (NSDUH), 86.3 percent of people ages 18 or older reported that they drank alcohol at some point in their lifetime.

Global Liver Diseases Therapeutics Market: Competitive Landscape

Major players operating in the global liver diseases therapeutics market include, Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.

Global Liver Diseases Therapeutics Market: Key Developments

Major players in the market are focused on adopting collaboration strategies to expand their product portfolio. For instance, in April 2020, Alnylam Pharmaceuticals, Inc. collaborated with Dicerna Pharmaceuticals, Inc. for the development and commercialization of investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease.

Major players in the market are also focused on approval and launch of generic therapies for the treatment of liver diseases. For instance, in September 2019, Endo International received the U.S. FDA approval for its generic version of Syprine, a drug used for the treatment of Wilson's disease.

Liver Diseases Therapeutics are used for treatment of hepatitis A, hepatitis B, and hepatitis C; liver fibrosis, liver cancer; fatty liver disease and cirrhosis; hemochromatosis and Wilson disease. Increasing prevalence of liver diseases such as liver fibrosis is expected to propel growth of the global liver diseases therapeutics market over the forecast period. Other factors influencing the growth of the market constitute of growing prevalence of risk factors such as chronic infection with hepatitis B or C virus, compromised immune system due to co-infection with HIV or use of immunosuppressive drugs after a liver transplant.

Furthermore, Increasing R&D of novel therapeutics for treatment of liver diseases is expected to offer lucrative growth opportunities for players in the global liver diseases therapeutics market

Key features of the study:

  • This report provides in-depth analysis of the Liver Diseases Therapeutics market  and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global Liver Diseases Therapeutics market  based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global Liver Diseases Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Liver Diseases Therapeutics market

Detailed Segmentation:

  • Liver Diseases Therapeutics Market, Therapy Type:
      • Anti-Rejection Drugs/Immunosuppressant’s
      • Chemotherapy Drugs
      • Targeted therapy
      • Vaccines
      • Anti-Viral Drugs
      • Immunoglobulin’s
      • Corticosteroids
  • Liver Diseases Therapeutics Market, By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
  • Liver Diseases Therapeutics Market, By Region:
    • North America
      • Therapy Type:
        • Anti-Rejection Drugs/Immunosuppressant’s
        • Chemotherapy Drugs
        • Targeted therapy
        • Vaccines
        • Anti-Viral Drugs
        • Immunoglobulin’s
        • Corticosteroids
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • Therapy Type:
        • Anti-Rejection Drugs/Immunosuppressant’s
        • Chemotherapy Drugs
        • Targeted therapy
        • Vaccines
        • Anti-Viral Drugs
        • Immunoglobulin’s
        • Corticosteroids
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Therapy Type:
        • Anti-Rejection Drugs/Immunosuppressant’s
        • Chemotherapy Drugs
        • Targeted therapy
        • Vaccines
        • Anti-Viral Drugs
        • Immunoglobulin’s
        • Corticosteroids
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Therapy Type:
        • Anti-Rejection Drugs/Immunosuppressant’s
        • Chemotherapy Drugs
        • Targeted therapy
        • Vaccines
        • Anti-Viral Drugs
        • Immunoglobulin’s
        • Corticosteroids
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Therapy Type:
        • Anti-Rejection Drugs/Immunosuppressant’s
        • Chemotherapy Drugs
        • Targeted therapy
        • Vaccines
        • Anti-Viral Drugs
        • Immunoglobulin’s
        • Corticosteroids
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Therapy Type:
        • Anti-Rejection Drugs/Immunosuppressant’s
        • Chemotherapy Drugs
        • Targeted therapy
        • Vaccines
        • Anti-Viral Drugs
        • Immunoglobulin’s
        • Corticosteroids
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Astellas Pharma Inc. *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Strategies
    • Bristol-Myers Squibb
    • Gilead Sciences
    • Glaxosmithkline Plc
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co. Inc.
    • Novartis AG
    • Sanofi S.A
    • Pfizer Inc.
    • Takeda Pharmaceutical
    • Valeant Pharmaceuticals
    • Watson Pharmaceuticals, Inc.
    • Theratechnologies Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Protagonist Therapeutics, Inc.
    • Dicerna Pharmaceuticals, Inc.
    • Endo International
    • Provectus Biopharmaceuticals Inc.
    • MAX BioPharma, Inc.
  • “*” marked represents similar segmentation in other categories in the respective section.
FAQ

Frequently Asked Questions

The global liver diseases therapeutics market was valued at US$ 11,854.7 Mn in 2019 and is forecast to reach a value of US$ 24,921.3 Mn by 2027 at a CAGR of 9.7% between 2020 and 2027.
Antiviral drugs segment held the major market share in 2019 owing to increasing demand for antiviral drugs.
Major factor driving the growth of global Liver Disease Therapeutics market during the forecast period include increasing prevalence of hepatitis, and increasing drug development.
Major factors hampering the growth of the Liver Disease Therapeutics market during the forecast period constitutes of high costs.
North America Liver Disease Therapeutics market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly subscribe for our latest news & articles.